The gender earnings gap has made headlines recently as political campaigns argue over the issues. But there is another gender gap that gets little attention: the adverse drug reaction risk for women. Why is the FDA ignoring this problem?
From unsafe medical devices to inadequate clinical trials for drugs, the U.S. Food and Drug Administration has turned a blind eye to the unique health concerns of women, putting them at risk for drug side effects and other healthcare concerns. The results have been devastating, not only to women but sometimes to their unborn children.
Unsafe drugs and inadequate clinical testing
The problem of gender bias in medical research, whether involving drugs or medical devices, is nothing new. Yet, the FDA has continued to overlook obvious voids in its processes that would better safeguard the health of women.